How much does one dose of infliximab cost?

Infliximab (Infliximab) is a monoclonal antibody drug targeting tumor necrosis factor α (TNF-α). It is widely used to treat a series of chronic, autoimmune inflammatory diseases. Its core mechanism of action is to neutralize TNF-α activity in the body, thereby inhibiting excessive immune responses, relieving inflammation and reducing tissue damage. Infliximab is commonly used to treat Crohn's disease (CD), ulcerative colitis, rheumatoid arthritis (RA), psoriatic arthritis, severe plaque psoriasis and ankylosing spondylitis. It has shown good clinical remission rates and improved quality of life in most patients.

In terms of usage, the drug is administered intravenously, with doses usually calculated based on the patient's weight and infused every 8 weeks or less. Due to the potential risks of infection, drug resistance and immune system abnormalities during its use, it must be operated in experienced medical institutions and subject to long-term monitoring.

Regarding drug prices, infliximab has been officially launched in China and has been included in the national medical insurance drug catalog. With health insurance support, its cost of use has been significantly reduced, but prices still vary depending on the version chosen. At present, in addition to the original brand "Remicade", there are many biosimilar drugs that have been approved on the market. When the original drug is not reimbursed, the price of each 100mg is more than 4,000 yuan, while the generic version can usually be as low as 2,000 yuan. In some provinces and cities, the price has dropped significantly after large-scale purchases.

Under the coverage of medical insurance policies, patients can apply for reimbursement based on the diagnosed disease, indications for medication and whether the medical institution is a designated unit of medical insurance. The reimbursement ratio for some indications can reach 70%-90%. In foreign markets, especially the United States, the price of original infliximab is significantly higher than domestically, with each bottle selling for more than US$2,000. Although there are also biosimilar drugs on the market, the overall level remains high, causing patients to rely on commercial insurance or assistance programs for payment.

Reference materials:https://www.drugs.com/infliximab.html